Richard G. Gray, MA, MSc, a professor of medical statistics at the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.

Overall, Gray notes, fewer breast cancer recurrences were seen in the 10-year tamoxifen group than in the 5-year group. In all, women who continue tamoxifen treatment had a 25 percent lower recurrence rate and a 23 percent lower breast cancer mortality rate.

View more from the 2013 ASCO Annual Meeting

Videos

Richard G. Gray, MA, MSc, from the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer. 

Richard G. Gray, MA, MSc

Articles

Richard Gray on a Longer Duration of Tamoxifen